(Q28298744)

5

Leonard Leibovici

0 references

Mical Paul

2

Mical Paul

0 references

Dafna Yahav

Dafna Yahav

1

1 reference

ORCID Public Data File 2021

Nadav Sarid

4

Lancet Infectious Diseases

Nadav Sarid

0 references

language of work or name

English

0 references

publication date

May 2007

0 references

published in

0 references

volume

7

0 references

issue

5

0 references

page(s)

338-48

0 references

cites work

Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Inducible amp C beta-lactamase producing gram-negative bacilli from blood stream infections: frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE)

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to beta-lactamase levels

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Cephalosporinase induction and cephalosporin resistance: a longstanding misinterpretation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Failure of cefepime therapy in treatment of Klebsiella pneumoniae bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Use of 27 parenteral antimicrobial agents in north of France hospitals.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Cefepime versus ceftazidime in the treatment of lower respiratory tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Cefepime versus cefotaxime in the treatment of lower respiratory tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

A randomized trial of cefepime and ceftazidime for the treatment of community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Cefepime versus ceftazidime as empiric therapy for fever in neutropenic patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Efficacy and safety of cefepime treatment in Chinese patients with severe bacterial infections: in comparison with ceftazidime treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Cefepime versus ceftazidime as empiric monotherapy for fever and neutropenia in children with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Cefepime versus cefotaxime for empirical treatment of bacterial pneumonia in HIV-infected patients: an open, randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

A randomized monocentric trial in febrile neutropenic patients: ceftriaxone and gentamicin vs cefepime and gentamicin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

A randomized trial of cefepime (BMY-28142) and ceftazidime for the treatment of pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Comparison of cefepime and ceftazidime in combination with amikacin in the empirical treatment of high-risk patients with febrile neutropenia: a prospective, randomized, multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Randomized comparison of cefepime and ceftazidime for treatment of skin, surgical wound, and complicated urinary tract infections in hospitalized subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Treatment of community-acquired pneumonia in the elderly: the role of cefepime, a fourth-generation cephalosporin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

International comparative study of cefepime and ceftazidime in the treatment of serious bacterial infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Clinical applications of a new parenteral antibiotic in the treatment of severe bacterial infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Randomized comparison of cefepime versus ceftazidime monotherapy for fever and neutropenia in children with solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Cefepime compared with ceftazidime as initial therapy for serious bacterial infections and sepsis syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

A comparative study of cefepime and ceftazidime in the treatment of community-acquired lower respiratory tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

A new therapeutic option for the treatment of pneumonia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Comparative study of cefepime versus ceftazidime in the empiric treatment of pediatric cancer patients with fever and neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Randomized comparative study of cefepime and cefotaxime in the treatment of acute obstetric and gynaecological infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Cefepime versus ceftazidime for the treatment of serious bacterial infections.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Prospective randomized comparison of cefepime and cefotaxime for treatment of bacterial meningitis in infants and children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

A comparative study of cefepime for bacterial pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

A comparative study of cefepime for chronic respiratory tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Cefepine vs. ceftazidime treatment of pyelonephritis: a European, randomized, controlled study of 300 pediatric cases. European Society for Paediatric Infectious Diseases (ESPID) Pyelonephritis Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Randomized comparison of cefepime and ceftazidime for treatment of hospitalized patients with gram-negative bacteremia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Current and future management of serious skin and skin-structure infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Treatment of urinary tract infections: selecting an appropriate broad-spectrum antibiotic for nosocomial infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination of 4th-generation cephalosporin + aminoglycosides: comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

A comparative study of cefepime versus ceftazidime as empiric therapy of febrile episodes in neutropenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Development of resistance during ceftazidime and cefepime therapy in a murine peritonitis model

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Nonconvulsive status epilepticus during cephalosporin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Nonconvulsive status epilepticus associated with cephalosporins in patients with renal failure.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Status epilepticus associated with cefepime

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Reversible coma secondary to cefepime neurotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Nonconvulsive status epilepticus associated with cefepime in a patient undergoing autologous stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Severe but reversible encephalopathy associated with cefepime

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Cefepime- and cefixime-induced encephalopathy in a patient with normal renal function

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Nonconvulsive status epilepticus due to cefepime in a patient with normal renal function

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Cephalosporin-induced nonconvulsive status epilepticus: clinical and electroencephalographic features

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Non-convulsive status epilepticus presenting as a psychiatric condition.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Efficacy of BMY-28142 in experimental bacteremia and meningitis caused by Escherichia coli and group B streptococci

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Antibacterial activity of BMY-28142, a novel broad-spectrum cephalosporin.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

In vitro and in vivo activities of amikacin, cefepime, amikacin plus cefepime, and imipenem against an SHV-5 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Comparison of in vivo intrinsic activity of cefepime and imipenem in a Pseudomonas aeruginosa rabbit endocarditis model: effect of combination with tobramycin simulating human serum pharmacokinetics.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Empiric use of cefepime in the treatment of serious urinary tract infections in children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Empiric use of cefepime in the treatment of lower respiratory tract infections in children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Antimicrobial therapy of unexplained fever in neutropenic patients--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeits

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Replacement of broad-spectrum cephalosporins by piperacillin-tazobactam: impact on sustained high rates of bacterial resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Restriction of third-generation cephalosporin use decreases infection-related mortality

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Impact of antibiotic changes in empirical therapy on antimicrobial resistance in intensive care unit-acquired infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Hospital-based strategies for combating resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021

Cefepime versus other beta-lactam antibiotics for the treatment of infections in non-neutropenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970109-3

7 January 2021